A Phase II Multicenter, Randomized, Placebo Controlled Study to Assess the Safety and Immunogenicity of an IM Influenza Vaccine (Multimeric-001) Followed by Administration of TIV to Elderly Volunteers.

Trial Profile

A Phase II Multicenter, Randomized, Placebo Controlled Study to Assess the Safety and Immunogenicity of an IM Influenza Vaccine (Multimeric-001) Followed by Administration of TIV to Elderly Volunteers.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Influenza virus vaccine (Primary) ; Aluminium phosphate
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors BiondVax Pharmaceuticals
  • Most Recent Events

    • 12 Jan 2017 Results presented at The Vaccine journal, as reported by a BiondVax Pharmaceuticals media release.
    • 12 Jan 2017 Results published in a BiondVax Pharmaceuticals media release.
    • 05 Jan 2017 Results published in the Vaccine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top